Published in Antimicrob Agents Chemother on July 01, 2003
Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev (2011) 1.90
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One (2009) 1.59
Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun (2005) 1.35
Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A (2008) 1.22
New concepts in antibody-mediated immunity. Infect Immun (2004) 1.19
Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest (2010) 1.16
Molecular chaperones in pathogen virulence: emerging new targets for therapy. Cell Host Microbe (2008) 1.14
Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov (2009) 1.14
Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe (2012) 1.07
Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun (2006) 1.01
Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol (2009) 1.00
Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect Immun (2007) 1.00
New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges. Front Microbiol (2012) 0.96
Serological profiling of a Candida albicans protein microarray reveals permanent host-pathogen interplay and stage-specific responses during candidemia. PLoS Pathog (2010) 0.96
Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections. J Infect Dis (2013) 0.96
Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin Vaccine Immunol (2011) 0.92
Modelling the regulation of thermal adaptation in Candida albicans, a major fungal pathogen of humans. PLoS One (2012) 0.90
Hybridoma passage in vitro may result in reduced ability of antimannan antibody to protect against disseminated candidiasis. Infect Immun (2006) 0.90
A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins. Proteomics (2009) 0.89
beta-Actin regulates platelet nitric oxide synthase 3 activity through interaction with heat shock protein 90. Proc Natl Acad Sci U S A (2007) 0.88
Host defense pathways against fungi: the basis for vaccines and immunotherapy. Front Microbiol (2012) 0.88
Vaccines in the treatment of invasive candidiasis. Virulence (2015) 0.86
Candida infections and their prevention. ISRN Prev Med (2012) 0.86
Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One (2012) 0.86
Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis. PLoS One (2011) 0.85
Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis. Antimicrob Agents Chemother (2011) 0.84
Antibody Peptide based antifungal immunotherapy. Front Microbiol (2012) 0.83
Pediatric Sepsis - Part V: Extracellular Heat Shock Proteins: Alarmins for the Host Immune System. Open Inflamm J (2011) 0.82
Dynamic duo takes down fungal villains. Proc Natl Acad Sci U S A (2009) 0.82
Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies. Antimicrob Agents Chemother (2006) 0.79
The relevance of heat shock regulation in fungal pathogens of humans. Virulence (2010) 0.79
Pathogen-specific antibodies: codependent no longer. J Clin Invest (2010) 0.79
Human monoclonal antibody-based therapy in the treatment of invasive candidiasis. Clin Dev Immunol (2013) 0.79
Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases. Front Microbiol (2015) 0.78
Emerging drugs and vaccines for candidemia. Mycoses (2014) 0.77
Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin. Antimicrob Agents Chemother (2009) 0.77
Nonspecific effect of Mycograb on amphotericin B MIC. Antimicrob Agents Chemother (2012) 0.77
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis. Front Microbiol (2017) 0.75
Functions of Antibodies. Microbiol Spectr (2014) 0.75
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis (1969) 5.58
Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature (1998) 4.65
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci (2000) 4.20
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis (2001) 3.68
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect (2002) 3.63
Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother (1996) 3.40
Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med J (Clin Res Ed) (1985) 2.74
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
Antifungal drug resistance of pathogenic fungi. Lancet (2002) 2.20
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol (1998) 2.09
Identification and molecular weight characterization of antigens from Candida albicans that are recognized by human sera. Infect Immun (1984) 2.05
Immunoblot analysis of the serological response in systemic candidosis. Lancet (1984) 1.90
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother (2002) 1.70
Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem (2000) 1.68
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother (2002) 1.61
Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J Clin Microbiol (1987) 1.58
Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology (1991) 1.49
The genome of Trypanosoma cruzi contains a constitutively expressed, tandemly arranged multicopy gene homologous to a major heat shock protein. Mol Cell Biol (1987) 1.46
Molecular cloning of sequences encoding the human heat-shock proteins and their expression during hyperthermia. Gene (1986) 1.42
Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test. J Clin Microbiol (1996) 1.34
A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem (2001) 1.34
Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob Agents Chemother (1997) 1.24
Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.23
In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother (2002) 1.23
Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob Agents Chemother (1995) 1.21
Candida and AIDS: evidence for protective antibody. Lancet (1988) 1.20
Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J Infect Dis (1995) 1.20
Cloning of a DNA sequence encoding a major fragment of the 47 kilodalton stress protein homologue of Candida albicans. FEMS Microbiol Lett (1989) 1.19
Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A (2002) 1.19
Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect (2002) 1.18
Structure and regulation of the HSP90 gene from the pathogenic fungus Candida albicans. Infect Immun (1995) 1.16
Single chain antibody variable regions. Trends Biotechnol (1991) 1.16
Murine 86- and 84-kDa heat shock proteins, cDNA sequences, chromosome assignments, and evolutionary origins. J Biol Chem (1989) 1.16
Enolase activity associated with a C. albicans cytoplasmic antigen. Yeast (1989) 1.08
Detection of Candida antigenuria in disseminated candidiasis by immunoblotting. J Clin Microbiol (1990) 1.07
Estrogen effects on Candida albicans: a potential virulence-regulating mechanism. J Infect Dis (2000) 1.07
Serologic analysis of antigen-specific reactivity in patients with systemic candidiasis. Diagn Microbiol Infect Dis (1985) 1.05
Isolation and characterization of a recombinant heat shock protein of Aspergillus fumigatus. J Allergy Clin Immunol (1993) 1.01
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother (1999) 1.01
Geldanamycin attenuates NO-mediated dilation in human skin. Am J Physiol Heart Circ Physiol (2002) 0.98
Stress proteins in fungal diseases. Med Mycol (1998) 0.97
The immunochemical characterisation of circulating immune complex constituents in Candida albicans osteomyelitis by isoelectric focusing, immunoblot, and immunoprint. Aust N Z J Med (1987) 0.97
Analysis of the serologic response to systemic Candida albicans infection in a murine model. Proteomics (2001) 0.95
The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis (2000) 0.95
Clinical relevance of antifungal resistance. Infect Dis Clin North Am (1997) 0.93
The application of epitope mapping in the development of a new serological test for systemic candidosis. J Immunol Methods (1991) 0.93
Heat shock protein 88 and Aspergillus infection. J Clin Microbiol (1991) 0.93
Developmental changes in the expression of Leishmania chagasi gp63 and heat shock protein in a human macrophage cell line. Infect Immun (1996) 0.92
Characterization of heat-inducible expression and cloning of HtpG (Hsp90 homologue) of Porphyromonas gingivalis. Infect Immun (2000) 0.91
Karyotyping of fluconazole-resistant yeasts with phenotype reported as Candida krusei or Candida inconspicua. Int J Syst Bacteriol (1996) 0.91
Autoantibodies to heat shock protein 90 in the human natural antibody repertoire. Int Immunol (2002) 0.90
Detection of candidal antigens in autoimmune polyglandular syndrome type I. Clin Diagn Lab Immunol (1996) 0.89
Detection of an antibody response in immunocompetent patients with systemic candidiasis or Candida albicans colonisation. Eur J Clin Microbiol Infect Dis (1990) 0.88
Characterisation and cellular localisation of the immunodominant 47-Kda antigen of Candida albicans. J Med Microbiol (1988) 0.88
Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother (2001) 0.87
Antifungal antibodies: a new approach to the treatment of systemic candidiasis. Curr Opin Investig Drugs (2001) 0.86
The Hsp90 of Candida albicans can confer Hsp90 functions in Saccharomyces cerevisiae: a potential model for the processes that generate immunogenic fragments of this molecular chaperone in C. albicans infections. Microbiology (1999) 0.83
Cell surface proteins of Candida albicans: preparation of extracts and improved detection of proteins. Electrophoresis (2000) 0.83
Western blot analysis of the immune response to Candida albicans antigens in 391 long-term intensive care patients. Mycoses (1997) 0.82
Expression of a cDNA encoding a Toxoplasma gondii protein belonging to the heat-shock 90 family and analysis of its antigenicity. FEMS Microbiol Lett (2000) 0.82
Immunogenicity and antigenicity of a Plasmodium falciparum protein fraction (90-110 kDa) able to protect squirrel monkeys against asexual blood stages. Vaccine (1994) 0.82
The 86-kilodalton antigen from Schistosoma mansoni is a heat-shock protein homologous to yeast HSP-90. Mol Biochem Parasitol (1989) 0.82
Isolation and identification of a 92-kDa stress induced protein from Candida albicans. Mycopathologia (1999) 0.81
Brugia malayi: the diagnostic potential of recombinant excretory/secretory antigens. Exp Parasitol (1994) 0.80
The expression of Candida albicans enolase is not heat shock inducible. FEMS Microbiol Lett (1994) 0.80
Epitope mapping human heat shock protein 90 with sera from infected patients. FEMS Immunol Med Microbiol (1994) 0.79
Survival after rupture of the oesophagus and subsequent candidal endocarditis: use of new serological methods in management. Eur Heart J (1989) 0.79
A PCR-based approach to sequence the Candida tropicalis HSP90 gene. FEMS Immunol Med Microbiol (2000) 0.77
HSP 90, yeasts and Corynebacterium jeikeium. Epidemiol Infect (1991) 0.77
Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections. Antimicrob Agents Chemother (2000) 0.76
A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis (2006) 4.29
Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res (2007) 1.06
Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. Tissue Eng Part A (2010) 1.03
Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. Radiother Oncol (2009) 1.02
IL18 haplotypes are associated with serum IL-18 concentrations in a population-based study and a cohort of individuals with premature coronary heart disease. Clin Chem (2007) 0.98
Recommendations for managing Aspergillus osteomyelitis and joint infections based on a review of the literature. J Infect (2005) 0.97
Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One (2010) 0.89
Molecular cloning and characterization of SmrA, a novel ABC multidrug efflux pump from Stenotrophomonas maltophilia. J Antimicrob Chemother (2009) 0.85
Critical structure movement in cervix brachytherapy. Radiother Oncol (2013) 0.85
Reviewing the molecular mechanisms which increase endometrial cancer (EC) risk in women with polycystic ovarian syndrome (PCOS): time for paradigm shift? Gynecol Oncol (2013) 0.83
Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemother (2008) 0.83
Identification of ABC transporters in vancomycin-resistant Enterococcus faecium as potential targets for antibody therapy. FEMS Immunol Med Microbiol (2002) 0.81
High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy (2009) 0.78
Enhancement of antibiotic susceptibility of Stenotrophomonas maltophilia using a polyclonal antibody developed against an ABC multidrug efflux pump. Can J Microbiol (2011) 0.77
I-125 seed planning: an alternative method of urethra definition. Radiother Oncol (2009) 0.76
The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. Gynecol Endocrinol (2014) 0.75
Corrigendum: Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2017) 0.75